10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 351 shares of the company’s stock in a transaction that occurred on Monday, November 22nd. The shares were sold at an average price of $148.38, for a total transaction of $52,081.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of 10x Genomics stock traded up $3.72 during trading hours on Thursday, reaching $150.99. The company’s stock had a trading volume of 759,885 shares, compared to its average volume of 722,448. 10x Genomics, Inc. has a one year low of $128.15 and a one year high of $208.99. The company has a market capitalization of $16.87 billion, a P/E ratio of -35.69 and a beta of 1.39. The stock’s fifty day simple moving average is $158.20 and its two-hundred day simple moving average is $169.61.
10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, November 3rd. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. 10x Genomics had a negative net margin of 99.17% and a negative return on equity of 6.30%. During the same period last year, the business earned ($0.33) EPS. As a group, equities analysts forecast that 10x Genomics, Inc. will post -0.42 earnings per share for the current year.
Several brokerages have issued reports on TXG. Bank of America cut shares of 10x Genomics from a “buy” rating to a “neutral” rating and set a $180.00 price target for the company. in a research report on Tuesday, September 14th. Citigroup decreased their price objective on shares of 10x Genomics from $240.00 to $220.00 and set a “buy” rating for the company in a research report on Thursday, August 5th. Zacks Investment Research cut shares of 10x Genomics from a “buy” rating to a “hold” rating in a research report on Friday, October 22nd. National Bank Financial started coverage on shares of 10x Genomics in a research note on Thursday, September 16th. They set a “sector perform” rating and a $24.00 target price on the stock. Finally, Morgan Stanley cut their target price on shares of 10x Genomics from $215.00 to $205.00 and set an “overweight” rating on the stock in a research note on Thursday, November 4th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, 10x Genomics currently has an average rating of “Buy” and a consensus price target of $172.50.
About 10x Genomics
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Story: Quiet Period
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.